Pulmonary damage in a patient with hairy cell leukemia - infectious involvement or hematological disease activity? Case report.
cladribine
hairy cell leukemia
interferon-alfa
pulmonary infiltration
Journal
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
ISSN: 1804-7521
Titre abrégé: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Pays: Czech Republic
ID NLM: 101140142
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
19
02
2022
accepted:
24
05
2022
pubmed:
18
6
2022
medline:
18
6
2022
entrez:
17
6
2022
Statut:
ppublish
Résumé
Hairy cell leukemia (HCL) is a rare indolent lymphoproliferative disease with an accumulation of mature B lymphocytes with fine reticular chromatin and cytoplasm with typical hairy-like cytoplasmic projections. Rarely, hairy cell leukemia manifests as a lung infiltration. The differential diagnosis between infection and malignant involvement with hairy cell leukemia is often challenging in such situations. We present a 53-year-old female with an uncommon pulmonary involvement with hairy cell leukemia. In addition, we discuss the complicated differential diagnosis of pulmonary disease in patients with hairy cell leukemia and the treatment approach to these patients. This case report describes the successful therapy management of a patient with pulmonary involvement by hairy cell leukemia. Therapy with interferon-alfa and cladribine resulted in long-term remission of the underlying disease.
Sections du résumé
BACKGROUND
BACKGROUND
Hairy cell leukemia (HCL) is a rare indolent lymphoproliferative disease with an accumulation of mature B lymphocytes with fine reticular chromatin and cytoplasm with typical hairy-like cytoplasmic projections. Rarely, hairy cell leukemia manifests as a lung infiltration. The differential diagnosis between infection and malignant involvement with hairy cell leukemia is often challenging in such situations.
METHODS AND RESULTS
RESULTS
We present a 53-year-old female with an uncommon pulmonary involvement with hairy cell leukemia. In addition, we discuss the complicated differential diagnosis of pulmonary disease in patients with hairy cell leukemia and the treatment approach to these patients.
CONCLUSION
CONCLUSIONS
This case report describes the successful therapy management of a patient with pulmonary involvement by hairy cell leukemia. Therapy with interferon-alfa and cladribine resulted in long-term remission of the underlying disease.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-389Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol 1993;85(4):714-7.
doi: 10.1111/j.1365-2141.1993.tb03213.x
Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. Am J Hematol 2017;92(12):1382-90.
doi: 10.1002/ajh.24936
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017;129(5):553-60.
doi: 10.1182/blood-2016-01-689422
Uzunhan Y, Cadranel J, Boissel N, Gardin C, Arnulf B, Bergeron A. Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas). Rev Mal Respir 2010;27(6):599-610.
doi: 10.1016/j.rmr.2010.05.002
Vardiman JW, Golomb HM. Autopsy findings in hairy cell leukemia. Semin Oncol 1984;11(4):370-80.
Hansen T, Constantin C, Weber M, Titze U, Hartmann F. Bronchoalveolar lavage in hairy cell leukemia with pulmonary infiltration. Pathologe 2019;40(5):529-33.
doi: 10.1007/s00292-019-0586-3
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 52-1982. A 50-year-old man with hairy-cell leukemia, recurrent fever, and variable pulmonary infiltrates. N Engl J Med 1982;307(27):1693-700.
Falini B, Tiacci E. New treatment options in hairy cell leukemia with focus on BRAF inhibitors. Hematol Oncol 2019;37(S1):30-7.
doi: 10.1002/hon.2594
Saven A, Piro LD. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin. Ann Intern Med 1993;119(4):278-83.
doi: 10.7326/0003-4819-119-4-199308150-00005
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci 2005;27(6):423-31.
doi: 10.1007/s11096-005-1319-7
Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman J, Burke JS. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol 1986;4(6):900-5.
doi: 10.1200/JCO.1986.4.6.900
Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15(11):1414-27. doi: 10.6004/jnccn.2017.0165
pubmed: 29118233
doi: 10.6004/jnccn.2017.0165
Park JH, Winer ES, Huntington SF, von Keudell G, Vemuri S, Shukla M, et al. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood 2021;138(Supplement 1):43.
doi: 10.1182/blood-2021-151074
Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102(12):3906-11.
doi: 10.1182/blood-2003-02-0630
Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018;32(8):1768-77.
doi: 10.1038/s41375-018-0210-1
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Foà R, Visani G, Zaja F, Falini B. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med 2021;384(19):1810-23.
doi: 10.1056/NEJMoa2031298